TN2019000187A1 - HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY - Google Patents
HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPYInfo
- Publication number
- TN2019000187A1 TN2019000187A1 TNP/2019/000187A TN2019000187A TN2019000187A1 TN 2019000187 A1 TN2019000187 A1 TN 2019000187A1 TN 2019000187 A TN2019000187 A TN 2019000187A TN 2019000187 A1 TN2019000187 A1 TN 2019000187A1
- Authority
- TN
- Tunisia
- Prior art keywords
- drug conjugates
- antibody drug
- adcs
- therapy
- based antibody
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 3
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 3
- 102000003964 Histone deacetylase Human genes 0.000 title abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163065.0A EP3381474A1 (en) | 2017-03-27 | 2017-03-27 | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
| PCT/EP2018/057744 WO2018178060A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2019000187A1 true TN2019000187A1 (en) | 2020-10-05 |
Family
ID=58448395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2019/000187A TN2019000187A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210128740A1 (enExample) |
| EP (2) | EP3381474A1 (enExample) |
| JP (1) | JP2020515578A (enExample) |
| KR (1) | KR20190126824A (enExample) |
| CN (1) | CN110475572A (enExample) |
| AU (1) | AU2018241840A1 (enExample) |
| BR (1) | BR112019013449A2 (enExample) |
| CA (1) | CA3047359A1 (enExample) |
| EA (1) | EA201991985A1 (enExample) |
| IL (1) | IL268821A (enExample) |
| MX (1) | MX2019011492A (enExample) |
| SG (2) | SG10202109654SA (enExample) |
| TN (1) | TN2019000187A1 (enExample) |
| UA (1) | UA125311C2 (enExample) |
| WO (1) | WO2018178060A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3930746A4 (en) * | 2019-02-25 | 2023-03-15 | Emory University | CHEMICAL COMPOUNDS AND METHODS OF MANAGING NEUROLOGICAL DISORDERS OR CONDITIONS |
| US20220401564A1 (en) * | 2019-11-06 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Selective histone deacetylase (hdac) degraders and methods of use thereof |
| JP2023534528A (ja) * | 2020-07-20 | 2023-08-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
| CN112430229B (zh) * | 2020-11-24 | 2023-03-21 | 福建医科大学 | 一种靶向降解parp蛋白的化合物及其制备方法与应用 |
| CN113292465B (zh) * | 2021-06-17 | 2022-11-08 | 贵州医科大学 | 一种半胱氨酸衍生物及其合成方法、应用 |
| US20250136619A1 (en) * | 2021-10-04 | 2025-05-01 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| EP4420682A1 (en) * | 2021-10-12 | 2024-08-28 | Chengdu Scimount Pharmatech Co., Ltd. | Highly-stable targeted linker-drug conjugate |
| CN118085013B (zh) * | 2022-11-25 | 2025-08-29 | 成都微芯新域生物技术有限公司 | 一种连接子、含连接子的抗体药物偶联物及其制备方法和应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN116554079B (zh) * | 2023-07-11 | 2023-11-10 | 南京市鸿舜医药科技有限公司 | 一种组蛋白去乙酰化酶抑制剂及用途 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025228384A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugates and use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| US8828392B2 (en) * | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| BRPI0911442A2 (pt) * | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| CA2915897A1 (en) * | 2013-07-05 | 2015-01-08 | Formation Biologics Inc. | Egfr antibody conjugates |
| CN106459205B (zh) * | 2014-04-11 | 2021-04-09 | 免疫医疗有限责任公司 | 包含半胱氨酸工程化抗体的轭合化合物 |
-
2017
- 2017-03-27 EP EP17163065.0A patent/EP3381474A1/en not_active Withdrawn
-
2018
- 2018-03-27 WO PCT/EP2018/057744 patent/WO2018178060A1/en not_active Ceased
- 2018-03-27 MX MX2019011492A patent/MX2019011492A/es unknown
- 2018-03-27 KR KR1020197028286A patent/KR20190126824A/ko not_active Withdrawn
- 2018-03-27 TN TNP/2019/000187A patent/TN2019000187A1/en unknown
- 2018-03-27 UA UAA201909898A patent/UA125311C2/uk unknown
- 2018-03-27 CN CN201880022128.4A patent/CN110475572A/zh active Pending
- 2018-03-27 CA CA3047359A patent/CA3047359A1/en active Pending
- 2018-03-27 AU AU2018241840A patent/AU2018241840A1/en not_active Abandoned
- 2018-03-27 SG SG10202109654S patent/SG10202109654SA/en unknown
- 2018-03-27 US US16/492,355 patent/US20210128740A1/en not_active Abandoned
- 2018-03-27 EA EA201991985A patent/EA201991985A1/ru unknown
- 2018-03-27 JP JP2019553113A patent/JP2020515578A/ja active Pending
- 2018-03-27 SG SG11201906543RA patent/SG11201906543RA/en unknown
- 2018-03-27 EP EP18712246.0A patent/EP3600444A1/en not_active Withdrawn
- 2018-03-27 BR BR112019013449A patent/BR112019013449A2/pt not_active IP Right Cessation
-
2019
- 2019-08-21 IL IL26882119A patent/IL268821A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018178060A1 (en) | 2018-10-04 |
| SG10202109654SA (en) | 2021-10-28 |
| EP3600444A1 (en) | 2020-02-05 |
| IL268821A (en) | 2019-10-31 |
| EP3381474A1 (en) | 2018-10-03 |
| SG11201906543RA (en) | 2019-08-27 |
| JP2020515578A (ja) | 2020-05-28 |
| MX2019011492A (es) | 2019-11-01 |
| CN110475572A (zh) | 2019-11-19 |
| CA3047359A1 (en) | 2018-10-04 |
| EA201991985A1 (ru) | 2020-02-25 |
| KR20190126824A (ko) | 2019-11-12 |
| UA125311C2 (uk) | 2022-02-16 |
| AU2018241840A1 (en) | 2019-10-03 |
| US20210128740A1 (en) | 2021-05-06 |
| BR112019013449A2 (pt) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2019000187A1 (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| MX2025009223A (es) | Agentes de union a clec9a y su uso | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
| EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| TN2017000554A1 (en) | Novel combination for use in the treatment of cancer | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201990425A1 (ru) | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение | |
| TW201613578A (en) | Pharmaceutical combinations | |
| EA201791225A1 (ru) | Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| MX2019010086A (es) | Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1. |